Heart failure remains a formidable cardiovascular challenge with high morbidity and mortality, especially for patients with reduced ejection fraction (HFrEF). CVRx’s FDA-approved Barostim device offers a novel approach by modulating autonomic nervous system imbalance via carotid baroreceptor stimulation, providing an alternative to existing therapies. Despite promising clinical validation and expanding commercial footprint generating $56.7 million revenue in 2025, the company faces ongoing losses and must manage regulatory and adoption hurdles to scale effectively. Its substantial liquidity positions it to pursue future growth opportunities while mitigating near-term risks.